Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Exogenous Administration of 15d-PGJ(2)-Loaded Nanocapsules Inhibits Bone Resorption in a Mouse Periodontitis Model

Full text
Author(s):
Napimoga, Marcelo H. [1] ; da Silva, Carlos A. T. [2] ; Carregaro, Vanessa [3] ; Farnesi-de-Assuncao, Thais S. [2] ; Duarte, Poliana M. [4] ; de Melo, Nathalie F. S. [5, 6] ; Fraceto, Leonardo F. [5, 6]
Total Authors: 7
Affiliation:
[1] Sao Leopoldo Mandic Inst & Res Ctr, Lab Immunol & Mol Biol, BR-13045755 Campinas, SP - Brazil
[2] Univ Fed Triangulo Mineiro, Immunol Lab, BR-38025180 Uberaba, MG - Brazil
[3] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Immunol, BR-14049900 Ribeirao Preto, SP - Brazil
[4] Univ Guarulhos, Dept Periodont, Dent Res Div, BR-07023070 Sao Paulo - Brazil
[5] Univ Estadual Campinas, Dept Biochem, BR-13083970 Campinas, SP - Brazil
[6] Sao Paulo State Univ, Dept Environm Engn, BR-18087180 Sorocaba, SP - Brazil
Total Affiliations: 6
Document type: Journal article
Source: JOURNAL OF IMMUNOLOGY; v. 189, n. 2, p. 1043-1052, JUL 15 2012.
Web of Science Citations: 25
Abstract

The 15-deoxy-(Delta 12,14)-PG J(2) (15d-PGJ(2)) has demonstrated excellent anti-inflammatory results in different experimental models. It can be used with a polymeric nanostructure system for modified drug release, which can change the therapeutic properties of the active principle, leading to increased stability and slower/prolonged release. The aim of the current study was to test a nano-technological formulation as a carrier for 15d-PGJ(2), and to investigate the immunomodulatory effects of this formulation in a mouse periodontitis model. Poly (D, L-lactide-coglycolide) nanocapsules (NC) were used to encapsulate 15d-PGJ(2). BALB/c mice were infected on days 0, 2, and 4 with Aggregatibacter actinomycetemcomitans and divided into groups (n = 5) that were treated daily during 15 d with 1, 3, or 10 mu g/kg 15d-PGJ(2)-NC. The animals were sacrificed, the submandibular lymph nodes were removed for FACS analysis, and the jaws were analyzed for bone resorption by morphometry. Immunoinflammatory markers in the gingival tissue were analyzed by reverse transcriptase-quantitative PCR, Western blotting, or ELISA. Infected animals treated with the 15d-PGJ(2)-NC presented lower bone resorption than infected animals without treatment (p < 0.05). Furthermore, infected animals treated with 10 mu g/kg 15d-PGJ(2)-NC had a reduction of CD4(+)CD25(+)FOXP3(+) cells and CD4/CD8 ratio in the submandibular lymph node (p < 0.05). Moreover, CD55 was upregulated, whereas RANKL was downregulated in the gingival tissue of the 10 mu g/kg treated group (p < 0.05). Several proinflammatory cytokines were decreased in the group treated with 10 mu g/kg 15d-PGJ(2)-NC, and high amounts of 15d-PGJ(2) were observed in the gingiva. In conclusion, the 15d-PGJ(2)-NC formulation presented immunomodulatory effects, decreasing bone resorption and inflammatory responses in a periodontitis mouse model. The Journal of Immunology, 2012, 189: 1043-1052. (AU)

FAPESP's process: 10/15014-9 - Evaluation of the effect of 15d-PGJ2-loaded on polymeric biodegradable nanoparticles to control the evolution of the experimental periodontal disease
Grantee:Marcelo Henrique Napimoga
Support Opportunities: Regular Research Grants